.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Julphar
QuintilesIMS
Covington
Chubb
Fuji
Cerilliant
McKinsey
Farmers Insurance
Daiichi Sankyo

Generated: September 20, 2017

DrugPatentWatch Database Preview

Ucb Inc Company Profile

« Back to Dashboard

What is the competitive landscape for UCB INC, and what generic alternatives to UCB INC drugs are available?

UCB INC has forty-eight approved drugs.

There are fifteen US patents protecting UCB INC drugs.

There are three hundred and nineteen patent family members on UCB INC drugs in forty-seven countries.

Summary for Applicant: Ucb Inc

Patents:15
Tradenames:32
Ingredients:24
NDAs:48
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION)021872-001Jul 31, 2006APRXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
BRIVIACT
brivaracetam
TABLET;ORAL205836-001May 12, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
BRIVIACT
brivaracetam
TABLET;ORAL205836-004May 12, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Ucb Inc
BRIVIACT
brivaracetam
TABLET;ORAL205836-003May 12, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
METADATE CD
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021259-006Feb 19, 2006AB2RXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
IONAMIN
phentermine resin complex
CAPSULE, EXTENDED RELEASE;ORAL011613-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
UNIVASC
moexipril hydrochloride
TABLET;ORAL020312-001Apr 19, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
AMITRIPTYLINE HYDROCHLORIDE
amitriptyline hydrochloride
TABLET;ORAL086335-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
FLUXID
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL021712-001Sep 24, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NEUPRO
rotigotine
FILM, EXTENDED RELEASE;TRANSDERMAL021829-002May 9, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
UNIRETIC
hydrochlorothiazide; moexipril hydrochloride
TABLET;ORAL020729-003Feb 14, 2002► Subscribe► Subscribe
Ucb Inc
KEPPRA XR
levetiracetam
TABLET, EXTENDED RELEASE;ORAL022285-001Sep 12, 2008► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-002Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;INTRAVENOUS022254-001Oct 28, 2008► Subscribe► Subscribe
Ucb Inc
UNIRETIC
hydrochlorothiazide; moexipril hydrochloride
TABLET;ORAL020729-002Jun 27, 1997► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-004Oct 28, 2008► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-001Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
SOLUTION;ORAL021505-001Jul 15, 2003► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION)021872-001Jul 31, 2006► Subscribe► Subscribe
Ucb Inc
UNIVASC
moexipril hydrochloride
TABLET;ORAL020312-001Apr 19, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for UCB INC drugs

Drugname Dosage Strength Tradename Submissiondate
rotigotine
Extended-release Transdermal Film1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr
NEUPRO
11/26/2013
lacosamide
Oral Solution10 mg/mL
VIMPAT
10/29/2012
lacosamide
Tablets50 mg, 100 mg, 150 mg, and 200 mg
VIMPAT
10/29/2012
levetiracetam
Extended-release Tablets1000 mg
KEPPRA XR
1/7/2011
metformin hydrochloride
Extended-release Capsules40 mg
METADATE CD
3/15/2007
levetiracetam
Tablets1000 mg
KEPPRA
1/24/2007
alprazolam
Orally Disintegrating Tablets0.25 mg, 0.5 mg, 1 mg and 2 mg
NIRAVAM
12/27/2005
metformin hydrochloride
Extended-release Capsules10 mg, 20 mg and 30 mg
METADATE CD
5/13/2005
moexipril hydrochloride and hydrochlorothiazide
Tablets7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg
UNIRETIC
1/15/2004

Non-Orange Book Patents for Ucb Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
7,217,8262-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,048,899 Anticonvulsant enantiomeric amino acid derivatives► Subscribe
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
8,034,9582-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
7,863,316Extended release formulation of Levetiracetam► Subscribe
5,773,475 Anticonvulsant enantiomeric amino acid derivatives► Subscribe
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
7,692,0282-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ucb Inc Drugs

Country Document Number Estimated Expiration
Malaysia138966► Subscribe
China101111245► Subscribe
Australia746856► Subscribe
Ukraine89216► Subscribe
Canada2248317► Subscribe
Germany60143493► Subscribe
Russian Federation2002124865► Subscribe
South Korea101016914► Subscribe
Japan4769756► Subscribe
Spain2355140► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ucb Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2006Austria► SubscribePRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 - EU/1/05/331/013 20060215
C0025France► SubscribePRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
2006 00020Denmark► Subscribe
24/2006Austria► SubscribePRODUCT NAME: ROTIGOTINE
C026/2006Ireland► SubscribeSPC026/2006:, EXPIRES: 20210214
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1033978/01Switzerland► SubscribePRODUCT NAME: ROTIGOTINE; REGISTRATION NUMBER/DATE: SWISSMEDIC 57417 27.09.2006
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C001/2009Ireland► SubscribeSPC001/2009: 20091013, EXPIRES: 20220316
2009 00001Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Johnson and Johnson
Federal Trade Commission
Deloitte
Chubb
Express Scripts
Merck
Farmers Insurance
Chinese Patent Office
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot